Godavari Biorefineries profit and loss

Latest FY26
Revenue
₹1,988cr+6.3% on FY25
EBITDA
₹127cr+22.6% on FY25
Net profit
₹3.5cr−₹23.4 cr in FY25
EPS
₹0.69−₹5.11 in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
2,0131,9881,870
13.512.216.7
2,0262,0001,887
Expenses
1,4691,4891,243
30.928.917.8
−45.8−91.4125
136135125
47.849.171.8
55.554.550.1
301299256
1,9941,9641,888
122127104
66.472.653.6
Profit
32.235.7−1.5
−31.1−31.10.0
1.04.6−1.5
0.90.70.2
−0.10.421.6
0.81.021.9
0.23.5−23.4
0.23.5−23.4
0.20.9−0.3
0.44.5−23.7
—3.5—
Per share
₹0.03₹0.69−₹5.11
₹0.03₹0.69−₹5.11
Other comprehensive income — detail
0.20.9−0.3
—−0.90.3
—3.5—
Per share — as-filed variants
₹0.03₹0.69−₹5.11
₹0.03₹0.69−₹5.11
Derived — gross profit (revenue − materials − purchases − Δ inventories)
558561485
27.7%28.2%25.9%
Adjusted (ex-exceptional items) — derived
32.235.7−1.5
−31.1−31.10.0
12.727.6−23.4
₹1.69₹5.39−₹5.11
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GODAVARIB₹207.28

Godavari Biorefineries Limited

· FMCG & Retail
AnnualQuarterly₹ CrorePeersDAVANGEREHNDFDSMcap ₹1,061 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,870.31,987.92,012.6
Other Income16.712.213.5
Total Income1,886.92,000.22,026.1
Expenses
+ Cost of Materials Consumed1,242.81,489.11,469.1
+ Purchases of Stock-in-Trade17.828.930.9
+ Changes in Inventories124.6-91.4-45.8
+ Employee Benefit Expense125.4135.2136.1
+ Finance Costs71.849.147.8
+ Depreciation & Amortisation50.154.555.5
+ Other Expenses256.1299.0300.5
Total Expenses1,888.51,964.41,993.9
EBITDA103.6127.1121.9
EBIT53.672.666.4
Profit
PBT before Exceptional Items-1.535.732.2
+ Exceptional Items0.0-31.1-31.1
Pretax Income-1.54.61.0
+ Current Tax0.20.70.9
+ Deferred Tax21.60.4-0.1
Tax Expense21.91.00.8
Net Income-23.43.50.2
+ Net Income — Continuing Ops-23.43.50.2
+ Other Comprehensive Income-0.30.90.2
Total Comprehensive Income-23.74.50.4
Net Income to Common—3.5—
Per Share
Basic EPS-5.110.690.03
Diluted EPS-5.110.690.03
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.30.90.2
+ Tax on Items NOT to be Reclassified0.3-0.9—
Comprehensive Income — Owners of Parent—3.5—
Per Share — as-filed variants
Basic EPS — Continuing Operations-5.110.690.03
Diluted EPS — Continuing Operations-5.110.690.03
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit485.1561.3558.5
Gross Margin %25.9428.2427.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-1.535.732.2
− Exceptional Items (reconciliation)0.0-31.1-31.1
Net Income Adj (tax-effected)-23.427.612.7
EPS Adj-5.115.391.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.00
Filed Debt Equity0.910.00—
Filed Dscr0.270.00—
Filed Iscr0.940.00—
Paid Up Equity Capital51.251.251.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.